Clinical trials: Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis
The aim of this study is to determine whether prophylactic vaccines recommended are effective and safe in patients with multiple sclerosis(MS) under MS-specific therapy.
- Trial name
- NCT02275741
- Testing
- prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)
- Where
- Germany
- Volunteers
- 226 people
- Sponsor
- Dr. med. Micha Loebermann
Secondary-progressive Multiple Sclerosis
Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients
This will be a phase I, open, multicenter, international study performed by 3 participating centres across two countries (Italy and Switzerland).
- Trial name
- NSC-SPMS (NCT03282760)
- Testing
- Human Neural Stem Cells
- Where
- 3 sites in Italy, Switzerland
- Volunteers
- 24 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Benign Paroxysmal Positional Vertigo, Multiple Sclerosis
Epley Manoeuvre in Participants With Multiple Sclerosis Diagnosed From Benign Paroxysmal Positional Vertigo
Vertigo, dizziness and control postural disturbance are one of the most disabling symptoms in Multiple Sclerosis. These could be caused by a peripheral or central vestibular disorder.
- Trial name
- NCT04578262
- Testing
- Epley Manoeuvre
- Volunteers
- 80 people
- Sponsor
- University of Seville
Relapsing Remitting Multiple Sclerosis
Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
Interleukin-2 (IL-2) was initially discovered and used as a stimulator of effector T lymphocytes (Teffs), but is now viewed as a very promising immunoregulatory drug having the capacity to stimulate regulatory T cells (Tregs).
- Trial name
- MS-IL2 (NCT02424396)
- Testing
- IL2
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Spinal Cord Injuries, Multiple Sclerosis
Functional and Physiological Responses to Lokomat Therapy (Pilot Study)
Individuals with neurological deficiencies such as those who have spinal cord injury, stroke, traumatic brain injury, Parkinson's disease, and multiple sclerosis often lose their ability to ambulate over ground.
- Conditions
- Spinal Cord Injuries, Multiple Sclerosis, Stroke
- Trial name
- NCT00883142
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- US Department of Veterans Affairs
Relapsing Multiple Sclerosis
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT04338022
- Testing
- Teriflunomide, Evobrutinib
- Where
- 279 sites in United States, Argentina and 29 more
- Volunteers
- 1,124 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Anxiety
Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis
The proposed trial is a prospective, randomized (1:1) trial plan examining whether more routine and frequent measurement of Patient Related Outcome Measures (PROMs) in the care of patients with MS improves patient depression and…
- Conditions
- Multiple Sclerosis, Anxiety, Depression, Patient Satisfaction
- Trial name
- NCT04979546
- Testing
- Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist, Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist
- Where
- Canada
- Volunteers
- 237 people
- Sponsor
- University of Alberta
Pediatric Multiple Sclerosis
Exercise Training in Pediatric-Onset Multiple Sclerosis Patients
Multiple sclerosis is one of the leading causes of disability in young adults. It is known that patients with pediatric onset multiple sclerosis (POMS) experience their first demyelinating attack before the age of 18.
- Trial name
- NCT04660227
- Testing
- Exercise Trainning, Control Group
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Istanbul University - Cerrahpasa
Relapsing Multiple Sclerosis, Multiple Sclerosis
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.
- Trial name
- NCT06104683
- Testing
- Pirtobrutinib
- Where
- 4 sites in United States, Puerto Rico
- Sponsor
- Loxo Oncology, Inc.
Falls Prevention
Vibration Training for Preventing Falls in Healthy Population and Multiple Sclerosis
This study is to investigate the effects of controlled whole-body vibration training on reducing the likelihood of falls among healthy population and people with multiple sclerosis.
- Trial name
- NCT02694666
- Testing
- Controlled whole-body vibration training
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Georgia State University
Multiple Sclerosis
Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis
Background: Transcranial Magnetic Stimulation (TMS) is a technique based on the principles of electromagnetic induction. It applies pulses of magnetic radiation that penetrate the brain tissue, and it is a non-invasive, painless…
- Trial name
- NCT04062331
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Volunteers
- 90 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Multiple Sclerosis, Covid-19
Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels
Hundreds of thousands of confirmed cases have been reported worldwide, just 3 months after the first patients were identified in Wuhan, China.
- Trial name
- NCT04438954
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Ankara Yildirim Beyazıt University
Multiple Sclerosis, Multiple Sclerosis Fatigue
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness.
- Trial name
- SOLARIMS (NCT06170970)
- Testing
- Solriamfetol
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis
Comparison of Robot-Assisted Gait Training and Conventional Therapy in Multiple Sclerosis Patients
The aim of this study is to compare conventional neurorehabilitation with robot-assisted gait training program in terms of fatigue, anxiety, depression and quality of life.
- Trial name
- NCT03801473
- Testing
- robot assisted gait therapy, Conventional rehabilitation
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Multiple Sclerosis
GSK239512 DDI Study
The study will determine the effect of 400 mg once daily of ketoconazole at steady state on the pharmacokinetics of a single oral dose of GSK239512 in young healthy volunteers.
- Trial name
- NCT01802931
- Testing
- GSK239512, ketoconazole
- Where
- Australia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Magnetic Resonance Imaging, Central Nervous System
Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions
Gadolinium-enhanced magnetic resonance imaging (MRI) is currently the imaging gold standard to detect active inflammatory lesions in multiple sclerosis (MS) patients.
- Conditions
- Magnetic Resonance Imaging, Central Nervous System, Brain, Multiple Sclerosis
- Trial name
- COGITE (NCT03268239)
- Testing
- Additional MRI sequences
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Remitting-Relapsing Multiple Sclerosis
TMP001 in Relapsing-remitting Multiple Sclerosis
The purpose of this study is to assess the impact of TMP001 in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT02686788
- Testing
- TMP001
- Where
- 5 sites in Germany
- Volunteers
- 9 people
- Sponsor
- Dr. Frank Behrens
Multiple Sclerosis
Capillary Dysfunction and CD46-immunoreceptor (CD46) Type in MS
This project aims to contribute knowledge to early MS disease mechanisms at the brain-blood interface using a combined immunological and neuroimaging approach.
- Trial name
- NCT03906370
- Testing
- Diagnostic criteria for MS
- Where
- Denmark
- Volunteers
- 83 people
- Sponsor
- University of Aarhus
Multiple Sclerosis, Stroke
PLasmatic Extracellular Vesicles AS Biomarkers of nEural Tissue Damage
Recently proposed central nervous system damage biomarkers detectable in biofluids, such as neurofilament light chain (NfL) have several limits, including a lack in specificity and a kinetic that does not allow them to be used as…
- Trial name
- PLEASE (NCT07769294)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Roberto Furlan
Multiple Sclerosis, Relapsing-Remitting
RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS
A randomized trial of long-term dosage of rituximab in multiple sclerosis
- Trial name
- RIDOSE-MS (NCT03979456)
- Testing
- Rituximab
- Where
- 17 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Karolinska Institutet